和元生物(688238) - 2025 Q4 - 年度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between -237 million to -195 million CNY, a reduction in loss of 84.81 million to 126.81 million CNY compared to the previous year, representing a decrease in loss of 26.35% to 39.41%[2] - The expected net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between -244 million to -201 million CNY, a reduction in loss of 91.91 million to 134.91 million CNY compared to the previous year, indicating a decrease in loss of 27.36% to 40.16%[2] - The total profit for the year 2024 was -312.63 million CNY, with a net profit attributable to shareholders of the parent company at -321.81 million CNY[4] - The financial data provided is preliminary and has not been audited by registered accountants, with the final figures to be disclosed in the audited annual report for 2025[8] Business Strategy - The company is focusing on its core business in cell and gene therapy CRO/CDMO, leveraging national and industry development policies to strategically position itself in the regenerative medicine application field[5] - The company aims to enhance customer resource reserves, improve brand influence, and promote industry development as part of its operational strategy[5] Industry Challenges - Despite a recovery in the cell and gene therapy industry starting in the second half of 2025, the CDMO business continues to face challenges due to insufficient downstream investment and financing, resulting in low customer order prices[6] - The company has conducted preliminary impairment testing on inventory, long-term assets, and contract orders due to the ongoing losses in the CDMO business, which has impacted the current net profit[6]